Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-β-D-maltoside

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 1912-1920

  Arnold, John J ^b   Fyrberg, Michael D ^a   Meezan, Elias ^a   Pillion, Dennis J ^a  

^a University of Alabama at Birmingham   (United States)

^b SAMFORD UNIVERSITY   (United States)

Author keywords

Alkylglycosides; Calcitonin; Drug delivery; Growth hormone; Insulin; Nasal

Indexed keywords

CALCITONIN; GLYCOSIDE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; PENETRATION ENHANCING AGENT; SALCATONIN; TETRADECYL BETA DEXTRO MALTOSIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APICAL MEMBRANE; ARTICLE; CELL JUNCTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; EUKARYOTIC FLAGELLUM; MALE; NONHUMAN; NOSE CAVITY; NOSE MUCOSA; PERMEABILITY BARRIER; RAT; TRANSMISSION ELECTRON MICROSCOPY;

EID: 77949869502     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21977     Document Type: Article

References (27)

1. McMartin C, Hutchinson LEF, Hyde R, Peters GE. 1987. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci 76:535-540.
2. Donovan MD, Huang Y. 1998. Large molecule particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Deliv Rev 29:147-155.
3. Pham DQ, Cohen H, Chu V. 2007. Inhaled human (rDNA origin) insulin, a novel formulation for diabetes mellitus. J Clin Pharmacol 47:890-903.
4. Siekmeier R, Scheuch G. 2008. Inhaled insulin - Does it become reality? J Physiol Pharmacol 59:81-113.
5. Edman P, Bjork E. 1992. Nasal delivery of peptide drugs. Adv Drug Deliv Rev 8:165-177.
6. Sayani AP, Chien YW. 1996. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Sys 13:85-184.
7. Ugwoke MI, Verbeke N, Kinget R. 2001. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 53:3-22.
8. Illum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326-1331.
9. Agerholm C, Bastholm L, Johansen PB,NielsenMH, Elling F. 1994. Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-α- phosphatidylcholine and α-cyclodextrin in rabbits. J Pharm Sci 83:1706-1711.
10. Yetkin G, Celebi N, Agabeyoglu I, Gokcora N. 1999. The effect of dimethyl-β-cyclodextrin and sodium taurocholate on the nasal bioavailability of salmon calcitonin in rabbits. STP Pharm Sci 3:249-252.
11. Pillion DJ, Ahsan F, Arnold JJ, Balusubramanian BM, Piraner O, Meezan E. 2002. Synthetic longchain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J Pharm Sci 91:1456-1462.
12. Balzer D, Luders H. 2000. Nonionic surfactants: Alkyl polyglucosides. New York: Marcel Dekker.
13. Hovgaard L, Jacobs H, Mazer NA, Wan KimS. 1996. Stabilization of insulin by alkylmaltosides. A spectroscopic evaluation. Int J Pharm 132:107-113.
14. Pillion DJ, Hosmer S, Meezan E. 1998. Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: Independence of surfactant action from multimer dissociation. Pharm Res 15:1637-1639.
15. Pillion DJ, Atchison JA, Gargiulo C, Wang R-X, Wang P, Meezan E. 1994. Insulin delivery in nosedrops: New formulations containing alkylglycosides. Endocrinology 135:1386-1391.
16. Pillion DJ, Wang P, Yorks J, McCann P, Meezan E. 1995. Systemic absorption of insulin and glucagon applied to the eyes of rats and diabetic dogs. J Ocul Pharmacol 11:283-295.
17. Ahsan F, Arnold J, Meezan E, Pillion DJ. 2001. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res 18:1742-1746.
18. Arnold J, Ahsan F, Meezan E, Pillion DJ. 2002. Nasal administration of low molecular weight heparin. J Pharm Sci 91:1707-1714.
19. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. 2004. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharm Sci 93:2205-2213.
20. -). Eur J Pharm Sci 20:27-34.
21. Chen-Quay SC, Eiting K, Li AW-A, Lamharzi N, Quay SC. 2009. Identification of tight junction modulating lipids. J Pharm Sci 98:606-619.
22. Monteiro-Riviere NA, Popp JA. 1984. Ultrastructural characterization of the nasal respiratory epithelium in the rat. Am J Anat 169:31-43.
23. Mygind N, Dahl R. 1998. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 29:3-12.
24. Epstein SP, Ahdoot M, Marcus E, Asbell PA. 2009. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. 25: 113-119.
25. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Metha P, Craft S. 2008. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448.
26. Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W. 2007. Intranasal insulin improves memory in humans: Superiority of insulin aspart. Neuropsychopharmacology 32:239-243.
27. Hallshmid M, Benedict C, Born J, Kern W. 2007. Targeting metabolic and cognitive pathways of the CNS by intranasal insulin administration. Expert Opin Drug Deliv 4:319-322.